Tags

Type your tag names separated by a space and hit enter

Oral contraceptives in polycystic ovary syndrome.
Minerva Endocrinol. 2014 Sep; 39(3):175-87.ME

Abstract

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder of women of reproductive age and combined oral contraceptives (OCs) are often the first-line treatment of the syndrome by improving hyperandrogenism and regulating menstrual cycles. Oral contraceptives have some cardiovascular and metabolic effects that varies among different formulations depending upon the dose and type of the both estrogen and progestin components. These cardiometabolic effects of OCs raise some concerns about their long-term use in PCOS, but available data suggest that the benefits outweigh the risks. More studies are needed to clarify the safety of long-term use of OCs in PCOS.

Authors+Show Affiliations

Division of Endocrinology and Metabolism Department of Internal Medicine Hacettepe University School of Medicine Hacettepe, Ankara, Turkey - yildizbo@yahoo.com.No affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

25003228

Citation

Helvaci, N, and B O. Yildiz. "Oral Contraceptives in Polycystic Ovary Syndrome." Minerva Endocrinologica, vol. 39, no. 3, 2014, pp. 175-87.
Helvaci N, Yildiz BO. Oral contraceptives in polycystic ovary syndrome. Minerva Endocrinol. 2014;39(3):175-87.
Helvaci, N., & Yildiz, B. O. (2014). Oral contraceptives in polycystic ovary syndrome. Minerva Endocrinologica, 39(3), 175-87.
Helvaci N, Yildiz BO. Oral Contraceptives in Polycystic Ovary Syndrome. Minerva Endocrinol. 2014;39(3):175-87. PubMed PMID: 25003228.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Oral contraceptives in polycystic ovary syndrome. AU - Helvaci,N, AU - Yildiz,B O, Y1 - 2014/07/08/ PY - 2014/7/9/entrez PY - 2014/7/9/pubmed PY - 2015/1/23/medline SP - 175 EP - 87 JF - Minerva endocrinologica JO - Minerva Endocrinol. VL - 39 IS - 3 N2 - Polycystic ovary syndrome (PCOS) is the most common endocrine disorder of women of reproductive age and combined oral contraceptives (OCs) are often the first-line treatment of the syndrome by improving hyperandrogenism and regulating menstrual cycles. Oral contraceptives have some cardiovascular and metabolic effects that varies among different formulations depending upon the dose and type of the both estrogen and progestin components. These cardiometabolic effects of OCs raise some concerns about their long-term use in PCOS, but available data suggest that the benefits outweigh the risks. More studies are needed to clarify the safety of long-term use of OCs in PCOS. SN - 0391-1977 UR - https://www.unboundmedicine.com/medline/citation/25003228/Oral_contraceptives_in_polycystic_ovary_syndrome_ L2 - http://www.minervamedica.it/index2.t?show=R07Y2014N03A0175 DB - PRIME DP - Unbound Medicine ER -